MP 110Alternative Names: MP-110
Latest Information Update: 19 Jan 2016
At a glance
- Originator Marathon Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Adrenocortical carcinoma
Most Recent Events
- 19 Jan 2016 Discontinued - Phase-III for Adrenocortical carcinoma in USA (unspecified route)